Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has shipped two LuViva® Advanced Cervical Scans to Indonesia to begin cervical cancer screening evaluations in the world’s fourth most populous country. Indonesia has more than 63 million women...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the fourth quarter and year ended December 31, 2014. Revenue and other income for the fourth quarter ended December 31, 2014 was approximately $185,000, including...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter and year ended...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. The company has been in...
The LuViva® Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish...
